Paris
France
31
2024-11-14
The entities that hold a legal rights for patent applications filed by inventor Tedgui Alain:
Alain Tedgui from Paris, FR has applied for patents for these inventions. The list has both pending applications and granted patents:
INTERLEUKIN 2 CHIMERIC CONSTRUCTS WITH TARGETING SPECIFICY TO INFLAMED TISSUES
#2 | 2020-12-03B cell depleting agent for the treatment of atherosclerosis
#3 | 2019-12-05A B Cell Depleting Agent for the Treatment of Atherosclerosis
#4 | 2018-12-27Methods and pharmaceutical compositions for the treatment of obesity
#5 | 2016-02-25Methods for Predicting Cardiovascular Mortality Risk
#6 | 2016-01-28Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
#7 | 2015-10-22SPLA2 CARDIOVASCULAR PROGNOSTIC AND DIAGNOSTIC MARKER
#8 | 2015-10-22METHODS FOR THE TREATMENT AND DIAGNOSIS OF ATHEROSCLEROSIS
#9 | 2015-04-16METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT
#10 | 2015-02-26Methods for the treatment of nonalcoholic steatohepatitis
#11 | 2015-02-19Method for use in the treatment of aneurysm
#12 | 2014-09-25METHODS FOR THE TREATMENT AND DIAGNOSIS OF ATHEROSCLEROSIS
#13 | 2014-01-02METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR EVENT IN A SUBJECT
#14 | 2013-08-29A B Cell Depleting Agent for the Treatment of Atherosclerosis
#15 | 2013-01-17Combination of sPLA2 type IIA mass and OXPL/APOB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
#16 | 2012-12-20COMPOSITION FOR THE TREATMENT OF ATHEROSCLEROSIS
#17 | 2012-08-16Use Of Adipose Tissue Cells For Initiating The Formation Of A Functional Vascular Network
#18 | 2012-07-05Combination of sPLA2 activity and oxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
#19 | 2012-05-10Methods for Predicting Cardiovascular Mortality Risk
#20 | 2012-03-29Use of IL-17 Polypeptides for Use in the Prevention or Treatment of Atherosclerosis
#21 | 2011-11-10A B Cell Depleting Agent for the Treatment of Atherosclerosis
#22 | 2011-09-22Combination of sPLA2 activity and OxPL/apoB cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event
#23 | 2010-11-18Method of treating peripheral vascular diseases using IL-18 inhibitors
#24 | 2010-10-14Methods for producing a non human model for aortic aneurysm
#25 | 2010-10-07Use of Measles Virus Nucleoprotein for Treating Atherosclerosis
#26 | 2009-12-31Use of sPLAactivity for the diagnosis of a cardiovascular event
#27 | 2009-08-27Composition for the treatment of atherosclerosis
#28 | 2008-05-08Tr1 cells for use in atherosclerosis
#29 | 2007-10-25Cardiovascular Prognostic and Diagnostic Marker
#30 | 2007-05-24Use of adipose tisue cells for initiating the formation of a fuctional vascular network
#31 | 2006-10-19Use of IL-18BP for treatment of peripheral vascular diseases
41150 ⎘